An Open Label, Single Center, Single Dose, Phase 1, First in Man Study of the Safety, Tolerability and Pharmacokinetic Profile of RBP-7000
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Indivior
- 09 May 2016 New trial record